MDG1014 / Medigene, BioNTech - LARVOL DELTA

MEDIGENE ANNOUNCES STRATEGY AND CORPORATE UPDATE (MediGene Press Release) - "Lead program, MDG1015, a TCR-T therapy for NY-ESO-1 combined with PD1-41BB Switch Receptor technology; at CTA /IND enabling phase, with submission planned for 2H 2024; Second program, MDG10xx, TCR-T therapies for yet undisclosed targets combined with PD1-41BB Switch Receptor technology; candidate selection to be announced 2H 2023."

IND • Pipeline update • Oncology • Solid Tumor